LLY

914.51

+0.93%↑

UNH

577.15

-0.55%↓

NVO

134.78

+2.03%↑

JNJ

164.87

-0.88%↓

ABBV

193.46

+0.25%↑

LLY

914.51

+0.93%↑

UNH

577.15

-0.55%↓

NVO

134.78

+2.03%↑

JNJ

164.87

-0.88%↓

ABBV

193.46

+0.25%↑

LLY

914.51

+0.93%↑

UNH

577.15

-0.55%↓

NVO

134.78

+2.03%↑

JNJ

164.87

-0.88%↓

ABBV

193.46

+0.25%↑

LLY

914.51

+0.93%↑

UNH

577.15

-0.55%↓

NVO

134.78

+2.03%↑

JNJ

164.87

-0.88%↓

ABBV

193.46

+0.25%↑

LLY

914.51

+0.93%↑

UNH

577.15

-0.55%↓

NVO

134.78

+2.03%↑

JNJ

164.87

-0.88%↓

ABBV

193.46

+0.25%↑

Home・Stock List・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Closed

Sector Healthcare

8.12 1.88

Buy Sell

Overview

Share price change

24h

Current

Min

7.97

Max

8.29

Key metrics
By Trading Economics
EPS	-0.172
Profit margin	-66.092
Employees	536

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+92.59 upside

Dividends
By Dow Jones
Next Earnings	31 Oct 2024

Market Stats
By TradingEconomics
Market Cap	41M 990M
Previous open	6.24
Previous close	8.12

News Sentiment

By Acuity

50%

122 / 366 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

6.1 / 7.65 Support & Resistance

BioCryst Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

19 Sept 2024, 23:50 UTC

Hot Stocks

Stocks to Watch: Nike, FedEx, Alliance Entertainment Holding, Arq

19 Sept 2024, 20:59 UTC

Earnings

FedEx Cuts Full-Year Outlook After Posting Lower Profit, Revenue in 1Q -- Update

19 Sept 2024, 20:41 UTC

Top News

Nike CEO John Donahoe to Retire

19 Sept 2024, 20:40 UTC

Earnings

FedEx Cuts Full-Year Outlook After Posting Lower Profit, Revenue in 1Q

19 Sept 2024, 23:24 UTC

Market Talk

Sims U.S. Business Shines, But Asia Headwinds Remain -- Market Talk

19 Sept 2024, 23:01 UTC

Top News

U.K. Consumers Turn Notably Gloomier, Survey Says

19 Sept 2024, 22:21 UTC

Market Talk

Earnings

FedEx Warns of Continued, Worsening Headwinds in 2Q -- Market Talk

19 Sept 2024, 22:17 UTC

Top News

Why Fed Rate Cuts Are Hurting Treasury Bonds -- Barrons.com

19 Sept 2024, 22:13 UTC

Market Talk

Earnings

FedEx Counts on Price Hikes to Help Hurting Top and Bottom Lines -- Market Talk

19 Sept 2024, 22:13 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

19 Sept 2024, 22:06 UTC

Earnings

FedEx Stock Is Down. Earnings Show Why The Fed Cut Rates. -- Barrons.com

19 Sept 2024, 21:46 UTC

Top News

Earnings

FedEx Cuts Full-Year Outlook After Posting Lower Profit, Revenue -- Update

19 Sept 2024, 21:06 UTC

Earnings

FedEx Stock Slumps. It Wasn't Just the Earnings That Were Bad. -- Barrons.com

19 Sept 2024, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

19 Sept 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

19 Sept 2024, 20:50 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

19 Sept 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

19 Sept 2024, 20:42 UTC

Earnings

FedEx Stock Skids, Set To Snap Support As Q1 Results Disappoint -- IBD

19 Sept 2024, 20:39 UTC

Top News

Dow, S&P 500 Hit Records After Rate Cut -- WSJ

19 Sept 2024, 20:12 UTC

Earnings

FedEx Unable to Provide FY25 EPS or Effective Tax Rate Outlook on GAAP Basis >FDX

19 Sept 2024, 20:12 UTC

Earnings

FedEx Cash On-Hand as of Aug 31 Was $5.9 B >FDX

19 Sept 2024, 20:11 UTC

Earnings

FedEx Stock Slumps. It Wasn't Just the Earnings That Were Bad. -- Barrons.com

19 Sept 2024, 20:11 UTC

Earnings

FedEx: 'Committed to Our Plan to Return $3.8 B to Stockholders This Fiscal Yr' >FDX

19 Sept 2024, 20:11 UTC

Earnings

FedEx Expects Recent Pricing Actions to Help Offset Weaker-Than-Expected Demand Trends >FDX

19 Sept 2024, 20:10 UTC

Top News

Dow Crosses 42000, Hits Record in Post-Fed Rally -- WSJ

19 Sept 2024, 20:10 UTC

Earnings

FedEx Reaffirms FY25 Capital Spending of $5.2 B >FDX

19 Sept 2024, 20:10 UTC

Earnings

FedEx Reaffirms Permanent Cost Reductions From DRIVE Transformation Program of $2.2 B >FDX

19 Sept 2024, 20:10 UTC

Earnings

FedEx Had Previously Forecast of Low-To-Mid Single Digit Percentage Increase in Rev for FY25>FDX

19 Sept 2024, 20:09 UTC

Earnings

FedEx Sees Low Single-Digit Percentage Rev Growth Rate Yr Over Yr for FY25>FDX

19 Sept 2024, 20:09 UTC

Earnings

FedEx Sees FY25 EPS $20 to $21 After Also Excluding Costs Related to Business Optimization Initiatives >FDX

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

92.59% upside

12 Months Forecast

Average 15.33 USD 92.59%

High 30 USD

Low 7 USD

Based on 9 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to BioCryst Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

6.1 / 7.65Support & Resistance

Recent bullish events outweigh bearish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

122 / 366 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.